The stock market closed higher on Tuesday as investors digested a flurry of earnings reports. They are also looking out for latest details on President Donald Trump’s tariff plans.
Overall, S&P 500 and NASDAQ were up 0.6% to 5,561 and 17,461, respectively.
Tweet of the Day
This is Bearish https://t.co/BKdKWlHfLx
— David Sharek (@GrowthStockGuy) April 24, 2025
Chart of the Day
Here is the ten-year chart of Hims & Hers Health (HIMS) as of April 29, 2025, when the stock was at $34.
The company has been getting a lot of revenue from its own GLP-1 weight loss drug, which is similar to Eli Lilly’s (LLY) drug Mounjaro and Nova’s Ozempic. However, the FDA recently ruled Hims & Hers’ drug be taken taken off the market place. This collaboration with Nova Nordisk is great for the company, as it removes legal risk and still gives the company a name-brand weight loss drug to offer its members. Profit margins will likely suffer.
David Sharek, Founder of School of Hard Stocks, likes this deal as Hims & Hers has removed its GLP-1 drug from the platform. It gives the company more credibility. Wegovy will have a subscription price of $499 per month.
HIMS is part of our Growth Portfolio and Aggressive Growth Portfolio.
